DTX-024 is a highly purified and clinically tested injectable neuromodulator derived from neurotoxins produced by Clostridium botulinum.

Aquavit Holdings is asking the US Food and Drug Administration for an additional IND for DTX-024, a treatment of palmar hyperhidrosis using the company’s patented microchannel technology. 

DTX-024 is a highly purified and clinically tested injectable neuromodulator derived from neurotoxins produced by Clostridium botulinum.

Alongside Aquavit's biosimilar program for its botulinum toxin, this will be the first in the world, indicated for palmar hyperhidrosis, approved by FDA.

Aquavit has recently bolstered its executive team.

Dr. David Crean, PhD, MBA is the new Chief Financial Officer of Aquavit Holdings. He started within biopharmaceutical companies more than 30 years ago, most notably at Allergan, an Abbvie Company, 

Dr. Churlsu Kwon, MD. PhD. MPH., is the new Chief Medical Officer. He is aneurosurgeon and neuroscientist. "The neurotoxin market is expanding rapidly, with increasing demand for innovative products and personalized treatment plans,” says Kwon, CMO of Aquavit, in a press release. “There is currently no FDA approval for palmar hyperhidrosis and through our novel route of administration we will be able to offer new solutions to meet the evolving needs of patients in pathologies that are extremely debilitating. The provision of access for this population is a step in the right direction towards improving their health and well-being. "